Report
Louis-Clément AZAIS d'UHART
EUR 112.46 For Business Accounts Only

Analyse court terme - AB SCIENCE SA : Proche du support

Notre précédent avis était négatif.
Nous sommes neutre.
La zone de support est proche, la baisse peut s'interrompre.
Underlying
AB Science SA

AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a new class of targeted molecules whose action is to modify signaling patways within cells. Co. targets diseases such as cancer, inflammatory diseases and central nervous system diseases, in both human and veterinary medecines. Co. has developed its own portfolio of molecules including masitinib, which has already been registered in Europe and the U.S.A. and is pursuing five phase 3 studies in human medecine, including studies in pancreatic cancer, GIST, metastatic melanoma, and studies in mastocytosis and severe persistent asthma.

Provider
Day By Day
Day By Day

​​DayByDay is an independent research company providing global macro and single stock analysis, recommendation and allocation based purely on behavioural finance methods. Those include long term cycle analysis, sentiment analysis, and technical trigger. DayByDay serves all clients in need of practical and precise publications to make effective market decisions, on any time horizon, from a few hours to a few years.

Analysts
Louis-Clément AZAIS d'UHART

Other Reports on these Companies
Other Reports from Day By Day

ResearchPool Subscriptions

Get the most out of your insights

Get in touch